Citations

Clear

1031 citation(s) found for "Clark, AS".

Proposed research criteria for prodromal behavioural variant frontotemporal dementia
Barker, Megan S. , Gottesman, Reena , Manoochehri, Masood , Chapman, Silvia , Brushaber, Danielle , Devick, Katrina L. , Domoto‐Reilly, Kimiko , Fields, Julie A. , Forsberg, Leah K. , Ghoshal, Nupur , Graff‐Radford, Neill R. , Heuer, Hilary W. , Kornak, John , Mackenzie, Ian R. , Masdeu, Joseph C. , Mendez, Mario F, Pascual, Belén , Staffaroni, Adam M. , Tartaglia, Maria Carmela , Boxer, Adam L. , Rosen, Howard J. , Rankin, Katherine P. , Cosentino, Stephanie , Rascovsky, Katya, Huey, Edward D. , Kaufer, Daniel , Onyike, Chiadi U. , Ritter, Aaron, Weıntraub, Sandra , Devick, Katrina L , Masdeu, Joseph C , Pascual, Belen , Boeve, Brad , Tartaglia, Maria Carmela , Domoto-Reilly, Kimiko , Appleby, Brian S. , Dickerson, Bradford Clark , Galasko, Douglas , Goldman, Jill , Grossman, Murray , Hsiung, Ging‐Yuek Robin , Knopman, David S. , Litvan, Irene , Mendez, Mario F, Boeve, Bradley F. , Foroud, Tatiana , Kremers, Walter K. , Léger, Gabriel C. , Roberson, Erik D.

Mayo Clinic

Brain | September 30, 2021 | Volume: 145 | Issue: 3 | Pages: 1079-1097

10.1093/brain/awab365 | PMID 35349636 Get It

Abstract At present, no research criteria exist for the diagnosis of prodromal behavioural variant frontotemporal dementia (bvFTD), though early detection is of high research importance. Thus, we sought to develop and validate a proposed set of research criteria for prodromal bvFTD, termed ‘mild behavioural and/or cognitive impairment in bvFTD’ (MBCI-FTD). Participants included 72 participants deemed to have prodromal bvFTD; this comprised 55 carriers of a pathogenic mutation known to cause frontotemporal lobar degeneration, and 17 individuals with autopsy-confirmed frontotemporal lobar degeneration. All had mild behavioural and/or cognitive changes, as judged by an evaluating clinician. Based on extensive clinical workup, the prodromal bvFTD group was divided into a Development Group (n = 22) and a Validation Group (n = 50). The Development Group was selected to be the subset of the prodromal bvFTD group for whom we had the strongest longitudinal evidence of conversion to bvFTD, and was used to develop the MBCI-FTD criteria. The Validation Group was the remainder of the prodromal bvFTD group and was used as a separate sample on which to validate the criteria. Familial non-carriers were included as healthy controls (n = 165). The frequencies of behavioural and neuropsychiatric features, neuropsychological deficits, and social cognitive dysfunction in the prodromal bvFTD Development Group and healthy controls were assessed. Based on sensitivity and specificity analyses, seven core features were identified: apathy without moderate-severe dysphoria, behavioural disinhibition, irritability/agitation, reduced empathy/sympathy, repetitive behaviours (simple and/or complex), joviality/gregariousness, and appetite changes/hyperorality. Supportive features include a neuropsychological profile of impaired executive function or naming with intact orientation and visuospatial skills, reduced insight for cognitive or behavioural changes, and poor social cognition. Three core features or two core features plus one supportive feature are required for the diagnosis of possible MBCI-FTD; probable MBCI-FTD requires imaging or biomarker evidence, or a pathogenic genetic mutation. The proposed MBCI-FTD criteria correctly classified 95% of the prodromal bvFTD Development Group, and 74% of the prodromal bvFTD Validation Group, with a false positive rate of <10% in healthy controls. Finally, the MBCI-FTD criteria were tested on a cohort of individuals with prodromal Alzheimer’s disease, and the false positive rate of diagnosis was 11–16%. Future research will need to refine the sensitivity and specificity of these criteria, and incorporate emerging biomarker evidence.
Clinical Considerations for Routine Auditory and Vestibular Monitoring in Patients With Cystic Fibrosis
Garinis, Angela C. , Poling, Gayla L. , Konrad‐Martin, Dawn , Hullar, Timothy E. , Burrows, Holly , Chisholm, Jennifer , Custer, Amy , Hawe, Laura Dreisbach, Hunter, Lisa L. , Marras, Theodore K. , Ortiz, Candice E., Petersen, Lucretia , Winthrop, Kevin , Zettner, Erika M., Clark, Khaya D. , Hungerford, Michelle, Vachhani, Jay J., Brewer, Carmen C. , Steyger, Peter S , Clark, Khaya , Poling, Gayla L , Rubenstein, Ronald C. , Baguley, David

Mayo Clinic

American Journal of Audiology | September 22, 2021 | Volume: 30 | Issue: 3S | Pages: 800-809

10.1044/2021_aja-21-00031 | PMID 34549989 Get It

Purpose Specific classes of antibiotics, such as aminoglycosides, have well-established adverse events producing permanent hearing loss, tinnitus, and balance and/or vestibular problems (i.e., ototoxicity). Although these antibiotics are frequently used to treat pseudomonas and other bacterial infections in patients with cystic fibrosis (CF), there are no formalized recommendations describing approaches to implementation of guideline adherent ototoxicity monitoring as part of CF clinical care. Method This consensus statement was developed by the International Ototoxicity Management Working Group (IOMG) Ad Hoc Committee on Aminoglycoside Antibiotics to address the clinical need for ototoxicity management in CF patients treated with known ototoxic medications. These clinical protocol considerations were created using consensus opinion from a community of international experts and available evidence specific to patients with CF, as well as published national and international guidelines on ototoxicity monitoring. Results The IOMG advocates four clinical recommendations for implementing routine and guideline adherent ototoxicity management in patients with CF. These are (a) including questions about hearing, tinnitus, and balance/vestibular problems as part of the routine CF case history for all patients; (b) utilizing timely point-of-care measures; (c) establishing a baseline and conducting posttreatment evaluations for each course of intravenous ototoxic drug treatment; and (d) repeating annual hearing and vestibular evaluations for all patients with a history of ototoxic antibiotic exposure. Conclusion Increased efforts for implementation of an ototoxicity management program in the CF care team model will improve identification of ototoxicity signs and symptoms, allow for timely therapeutic follow-up, and provide the clinician and patient an opportunity to make an informed decision about potential treatment modifications to minimize adverse events. Supplemental Material https://doi.org/10.23641/asha.16624366
Assessment of Residual Cancer Burden and Event-Free Survival in Neoadjuvant Treatment for High-risk Breast Cancer
Symmans, W. Fraser , Chen, Yunn-Yi, Klein, Molly, Nanda, Rita , Parker, Barbara A. , Datnow, Brian, Krings, Gregor , Wei, Shi , Duan, Xiuzhen, Chen, Beiyun, Sattar, Husain, Khazai, Laila , Zeck, Jay , Sams, Sharon B. , Mhawech‐Fauceglia, Paulette , Rendi, Mara H. , Sahoo, Sunati , Ocal, Idris Tolgay, Fan, Fang, LeBeau, Lauren, Vinh, Tuyethoa N., Troxell, Megan L. , Chien, A. Jo , Forero‐Torres, Andres , Ellis, Erin D. , Albain, Kathy S. , Liu, Minetta C. , Haley, Barbara , Clark, Amy S. , Kemmer, Kathleen, Lang, Julie E. , Edmiston, Kirsten K., Viscusi, Rebecca K., Northfelt, Donald W. , Khan, Qamar J. , Leyland‐Jones, Brian , Venters, Sara J., Shad, Sonal , Matthews, Jeffrey B. , Asare, Smita , Buxton, Meredith , Asare, Adam L. , Schwab, Richard B. , Veer, Laura van ‘t , Perlmutter, Jane , Yee, Douglas , Berry, Donald A. , Esserman, Laura J. , Symmans, W Fraser , Esserman, Laura J , Asare, Adam L , Yee, Douglas , Yau, Christina , Chen, Yunn‐Yi , Balassanian, Ronald , Pusztai, Lajos , Feldman, Michael D. , Wallace, Anne M. , Murthy, Rashmi Krishna , Boughey, Judy C. , Elias, Anthony , Isaacs, Claudine , Han, Hyo S , Matthews, Jeffrey B., Rugo, Hope S. , Helsten, Teresa L. , Hylton, Nola M. , Veer, Laura J. van’t , DeMichele, Angela

Mayo Clinic

JAMA Oncology | September 16, 2021 | Volume: 7 | Issue: 11 | Pages: 1654

10.1001/jamaoncol.2021.3690 | PMID 34529000 Get It

Thyrotropin-Receptor Antibody Positivity Does Not Correlate with Type 1 or Type 2 Amiodarone-Induced Thyrotoxicosis Phenotype
Clark, Jennifer , Stan, Marius N.

Mayo Clinic

Clinical Thyroidology | September 13, 2021 | Volume: 33 | Issue: 9 | Pages: 388-390

10.1089/ct.2021;33.388-390 Get It

The Management of Cancer Symptoms and Treatment-Induced Side Effects With Cannabis or Cannabinoids
Sexton, Michelle , Garcia, José M. , Jatoi, Aminah , Clark, Carey S. , Wallace, Mark S. , Garcia, Jose M

Mayo Clinic

JNCI Monographs | September 8, 2021 | Volume: 2021 | Issue: 58 | Pages: 86-98

10.1093/jncimonographs/lgab011 | PMID 34850897 Get It

Abstract Cannabis and cannabinoids are increasingly being accessed and used by patients with advanced cancer for various symptoms and general quality of life. Specific symptoms of pain, nausea and vomiting, loss of appetite and cachexia, anxiety, sleep disturbance, and medical trauma are among those that have prompted patients with cancer to use cannabis. This conference report from the National Cancer Institute’s “Cannabis, Cannabinoid and Cancer Research Symposium” on the topic of “Cancer Symptom/Treatment Side Effect Management” is an expert perspective of cannabis intervention for cancer and cancer treatment-related symptoms. The purpose of the symposium was to identify research gaps, describe the need for high-quality randomized prospective studies of medical cannabis for palliative care in patients with cancer, and evaluate the impact of medical cannabis on cancer survivors’ quality of life. Further, education of clinicians and affiliated health-care providers in guiding cancer patients in using cannabis for cancer care would benefit patients. Together, these steps will further aid in refining the use of cannabis and cannabinoids for symptom palliation and improve safety and efficacy for patients.
Assessing Change in Communication Limitations in Primary Progressive Apraxia of Speech and Aphasia: A 1-Year Follow-Up Study
Utianski, Rene L. , Martin, Peter R. , Botha, Hugo , Clark, Heather M. , Josephs, Keith A. , Botha, Hugo , Clark, Heather M , Josephs, Keith A , Utianski, Rene L , Duffy, Joseph R.

Mayo Clinic

American Journal of Speech-Language Pathology | September 7, 2021 | Volume: 30 | Issue: 6 | Pages: 2368-2378

10.1044/2021_ajslp-20-00402 | PMID 34491800 Get It

Purpose Individuals with primary progressive apraxia of speech have apraxia of speech (AOS) as the initial and predominant symptom. Many develop aphasia and/or dysarthria later in the disease course. It was previously demonstrated that patients with neurodegenerative AOS experience reduced participation in communication that is further exacerbated by co-occurring language deficits ( Utianski et al., 2020 ). Measures of disease severity did not necessarily correlate with measures of participation restrictions. The aim of this follow-up study was to describe changes in communication limitations in these patients, again measured by (a) the patient via the Communicative Participation Item Bank (CPIB) and (b) the speech-language pathologist via the American Speech-Language-Hearing Association's (ASHA's) Functional Communication Measures (FCMs) and an adapted motor speech disorder (MSD) severity rating to determine if there are significant changes in these and other objective speech and language measures at follow-up after 1 year. Method Of the 24 patients reported in the study of Utianski et al. (2020) , 17 (10 men, seven women) returned for a second visit approximately 1 year following the first visit. Identical procedures were utilized; the communication measures collected at each visit were statistically compared. Correlations were calculated between the participation ratings and other clinical assessment measures at the second visit and for the change in scores on those measures between the first and second visits. Results There were statistically significant differences in AOS and aphasia severity between visits. There were significant changes in clinical assessments, MSD severity rating, and all ASHA FCMs between visits, but not the CPIB. Correlation analyses suggest the relationships among clinical and participation measures are complex; overall, patients with more severe changes in AOS experienced greater changes in participation restrictions. Conclusions The findings of this study support the use of patient-reported outcome measures as they may better reflect the patient experience, including the influence of factors such as ongoing speech therapy and the emergence of neuropsychiatric features, and associated changes in day-to-day functioning, when other measures may simply index the progression of the disease. Supplemental Material https://doi.org/10.23641/asha.16528512
Designed architectural proteins that tune DNA looping in bacteria
Tse, David, Becker, Nicole A. , Young, Robert T. , Peters, Justin P. , Schwab, Tanya L., Maher, L. James , Tse, David H, III, Louis James Maher , Olson, Wilma K. , Clark, Karl J.

Mayo Clinic

Nucleic Acids Research | September 3, 2021 | Volume: 49 | Issue: 18 | Pages: 10382-10396

10.1093/nar/gkab759 | PMID 34478548 Get It

Abstract Architectural proteins alter the shape of DNA. Some distort the double helix by introducing sharp kinks. This can serve to relieve strain in tightly-bent DNA structures. Here, we design and test artificial architectural proteins based on a sequence-specific Transcription Activator-like Effector (TALE) protein, either alone or fused to a eukaryotic high mobility group B (HMGB) DNA-bending domain. We hypothesized that TALE protein binding would stiffen DNA to bending and twisting, acting as an architectural protein that antagonizes the formation of small DNA loops. In contrast, fusion to an HMGB domain was hypothesized to generate a targeted DNA-bending architectural protein that facilitates DNA looping. We provide evidence from Escherichia coli Lac repressor gene regulatory loops supporting these hypotheses in living bacteria. Both data fitting to a thermodynamic DNA looping model and sophisticated molecular modeling support the interpretation of these results. We find that TALE protein binding inhibits looping by stiffening DNA to bending and twisting, while the Nhp6A domain enhances looping by bending DNA without introducing twisting flexibility. Our work illustrates artificial approaches to sculpt DNA geometry with functional consequences. Similar approaches may be applicable to tune the stability of small DNA loops in eukaryotes.
Baseline Cognitive Impairment in Patients With Asymptomatic Carotid Stenosis in the CREST-2 Trial
Lazar, Ronald M. , Wadley, Virginia G., Myers, Terina , Jones, Michael R., Heck, Donald V., Clark, Wayne M. , Marshall, Randolph S. , Howard, Virginia J., Voeks, Jenifer H., Manly, Jennifer J. , Moy, Claudia S., Chaturvedi, Seemant, Meschia, James F., Lal, Brajesh K. , Brott, Thomas G., Howard, George, Howard, Virginia J. , Howard, Virginia J , Manly, Jennifer J , Lazar, Ronald M , Wadley, Virginia G., Myers, Terina , Jones, Michael R., Heck, Donald V., Clark, Wayne M. , Marshall, Randolph S. , Voeks, Jenifer H., Moy, Claudia S., Chaturvedi, Seemant, Meschia, James F., Lal, Brajesh , Brott, Thomas G., Howard, George

Mayo Clinic

Stroke | August 26, 2021 | Volume: 52 | Issue: 12 | Pages: 3855-3863

10.1161/strokeaha.120.032972 | PMID 34433306 Get It

Background and Purpose: Studies of carotid artery disease have suggested that high-grade stenosis can affect cognition, even without stroke. The presence and degree of cognitive impairment in such patients have not been reported and compared with a demographically matched population-based cohort. Methods: We studied cognition in 1000 consecutive CREST-2 (Carotid Revascularization and Medical Management for Asymptomatic Carotid Stenosis Trial) patients, a treatment trial for asymptomatic carotid disease. Cognitive assessment was after randomization but before assigned treatment. The cognitive battery was developed in the general population REGARDS Study (Reasons for Geographic and Racial Differences in Stroke), involving Word List Learning Sum, Word List Recall, and Word List fluency for animal names and the letter F. The carotid stenosis patients were >45 years old with ≥70% asymptomatic carotid stenosis and no history of prevalent stroke. The distribution of cognitive performance for the patients was standardized, accounting for age, race, and education using performance from REGARDS, and after further adjustment for hypertension, diabetes, dyslipidemia, and smoking. Using the Wald Test, we tabulated the proportion of Z scores less than the anticipated deviate for the population-based cohort for representative percentiles. Results: There were 786 baseline assessments. Mean age was 70 years, 58% men, and 52% right-sided stenosis. The overall Z score for patients was significantly below expected for higher percentiles ( P <0.0001 for 50th, 75th, and 95th percentiles) and marginally below expected for the 25th percentile ( P =0.015). Lower performance was attributed largely to Word List Recall ( P <0.0001 for all percentiles) and for Word List Learning (50th, 75th, and 95th percentiles below expected, P ≤0.01). The scores for left versus right carotid disease were similar. Conclusions: Baseline cognition of patients with severe carotid stenosis showed below normal cognition compared to the population-based cohort, controlling for demographic and cardiovascular risk factors. This cohort represents the largest group to date to demonstrate that poorer cognition, especially memory, in this disease. Registration: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT02089217.
Interaction Time with Electronic Health Records: A Systematic Review
Pinevich, Yuliya , Clark, Kathryn J. , Harrison, Andrew M. , Pickering, Brian W. , Harrison, Andrew Marc , Clark, Kathryn , Herasevich, Vitaly

Mayo Clinic

Applied Clinical Informatics | August 25, 2021 | Volume: 12 | Issue: 04 | Pages: 788-799

10.1055/s-0041-1733909 | PMID 34433218 Get It

Abstract Background The amount of time that health care clinicians (physicians and nurses) spend interacting with the electronic health record is not well understood. Objective This study aimed to evaluate the time that health care providers spend interacting with electronic health records (EHR). Methods Data are retrieved from Ovid MEDLINE(R) and Epub Ahead of Print, In-Process and Other Non-Indexed Citations and Daily, (Ovid) Embase, CINAHL, and SCOPUS. Study Eligibility Criteria Peer-reviewed studies that describe the use of EHR and include measurement of time either in hours, minutes, or in the percentage of a clinician's workday. Papers were written in English and published between 1990 and 2021. Participants All physicians and nurses involved in inpatient and outpatient settings. Study Appraisal and Synthesis Methods A narrative synthesis of the results, providing summaries of interaction time with EHR. The studies were rated according to Quality Assessment Tool for Studies with Diverse Designs. Results Out of 5,133 de-duplicated references identified through database searching, 18 met inclusion criteria. Most were time-motion studies (50%) that followed by logged-based analysis (44%). Most were conducted in the United States (94%) and examined a clinician workflow in the inpatient settings (83%). The average time was nearly 37% of time of their workday by physicians in both inpatient and outpatient settings and 22% of the workday by nurses in inpatient settings. The studies showed methodological heterogeneity. Conclusion This systematic review evaluates the time that health care providers spend interacting with EHR. Interaction time with EHR varies depending on clinicians' roles and clinical settings, computer systems, and users' experience. The average time spent by physicians on EHR exceeded one-third of their workday. The finding is a possible indicator that the EHR has room for usability, functionality improvement, and workflow optimization.